Study	Method	Participants	Interventions	Primary outcome(s)	Setting	Disease severity	Overall risk of bias	Narrative of efficacy findings (95% CIs)	Narrative of safety findings
ACTG120, 1992	Single arm trial	59 with PDH	ITRA 300 mg BD for 3 days then 200 mg BD for 12 weeks	"Response to therapy" Death	USA	Mild to moderate	Serious	Clinical success: 50/59 participants 85% (73% to 93%) Death: 1/59	2/59 participants withdrew due to adverse events, and responded to AmB.
ACTG174, 1994	Single arm trial	49 with PDH	Initial protocol FCN 1200 mg, then 600 mg OD for 8 weeks Revised protocol FCN 1200 mg, then 80 mg OD for 8 weeks	"Treatment response"	USA	Mild to moderate	Serious	Clinical success: 36/49 participants. 74% (59% to 85%) Revised protocol	2 discontinuations due to toxicity, unclear if induction or maintenance.
Johnson 2002	RCT	81 with PDH	lAmB (55 participants) dAmB (26 participants)	Efficacy: "Clinical success" Safety: early discontinuation	USA	Moderate to severe	Low	Clinical success: lAmB: 82% (69% to 91%) 45/55 participants. dAmB: 56% (37% to 76%) 14/25 participants. RR 1.46 (1.01 to 2.11) Death: lAmB: 1/53 (2%) dAmB: 3/24 (13%) RR 0.15 (0.02 to 1.38)	Early discontinuation: 1/53 (2%) with lAmB vs 2/24 (8%) with dAmB RR 0.23 (95% CI 0.02 to 2.38) Nephrotoxicity: 5/53 (9%) with lAmB vs 9/24 (37%) with dAmB RR 0.25 (95% CI 0.09 to 0.67) Of note, authors did not report specific data in relation to other commonly recognized adverse effects, including anaemia.
Luckett 2015	Retrospective cohort study	56 with HIV and PDH	ITRA/VORI/POSA AmB	Death (90‐day histoplasmosis‐related) Triazole failure	USA	Mild to severe	Serious	Death 5/56 participants. Not reported by treatment regimen. Clinical success: triazole induction successful in 20/24 participants 83% (62% to 95%)	No safety issues reported.
AmB: amphotericin B; BD: twice daily; CI: confidence interval; dAmB: deoxycholate amphotericin B; FCN: fluconazole; ITRA: itraconazole; IAmB: liposomal amphotericin B; n: number of participants; OD: once daily; PDH: progressive disseminated histoplasmosis; POSA: posaconazole; RCT: randomized controlled trial; RR: risk ratio; VORI: voriconazole.